Education
About Us
Working with TipRanks
Follow Us
Novabay Pharmaceuticals (NBY)
:NBY
Total Valuation
NovaBay Pharma has a market cap or net worth of $3.31M. The enterprise value is -$3.91M.
Market Cap$3.31M
Enterprise Value-$3.91M
Share Statistics
NovaBay Pharma has 5,816,204 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,816,204
Owned by Insiders17.20%
Owned by Institutions5.00%
Financial Efficiency
NovaBay Pharma’s return on equity (ROE) is 55.99 and return on invested capital (ROIC) is -378.42%.
Return on Equity (ROE)55.99
Return on Assets (ROA)-2.11
Return on Invested Capital (ROIC)-378.42%
Return on Capital Employed (ROCE)-10.07
Revenue Per Employee752.38K
Profits Per Employee-546.08K
Employee Count13
Asset Turnover2.86
Inventory Turnover4.31
Valuation Ratios
The current PE Ratio of NovaBay Pharma is -0.28. NovaBay Pharma’s PEG ratio is <0.01.
PE Ratio-0.28
PS Ratio0.00
PB Ratio0.51
Price to Fair Value-15.82
Price to FCF-0.70
Price to Operating Cash Flow-0.64
PEG Ratio<0.01
Income Statement
In the last 12 months, NovaBay Pharma had revenue of 9.78M and earned -7.22M in profits. Earnings per share was -2.53.
Revenue9.78M
Gross Profit6.48M
Operating Income-5.84M
Pretax Income-7.21M
Net Income-7.22M
EBITDA-5.92M
Earnings Per Share (EPS)-2.53
Cash Flow
In the last 12 months, operating cash flow was -4.92M and capital expenditures -4.00K, giving a free cash flow of -4.92M billion.
Operating Cash Flow-4.92M
Free Cash Flow-4.92M
Free Cash Flow per Share-0.85
Dividends & Yields
NovaBay Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.30
52-Week Price Change-87.64%
50-Day Moving Average0.58
200-Day Moving Average0.61
Relative Strength Index (RSI)47.27
Average Volume (3m)46.82K
Important Dates
NovaBay Pharma upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
NovaBay Pharma as a current ratio of 0.68, with Debt / Equity ratio of 18.24%
Current Ratio0.68
Quick Ratio0.41
Debt to Market Cap0.28
Net Debt to EBITDA-0.21
Interest Coverage Ratio-6.46
Taxes
In the past 12 months, NovaBay Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
NovaBay Pharma EV to EBITDA ratio is -0.55, with an EV/FCF ratio of -0.63.
EV to Sales0.34
EV to EBITDA-0.55
EV to Free Cash Flow-0.63
EV to Operating Cash Flow-0.63
Balance Sheet
NovaBay Pharma has $8.47M in cash and marketable securities with $1.13M in debt, giving a net cash position of -$7.34M billion.
Cash & Marketable Securities$8.47M
Total Debt$1.13M
Net Cash-$7.34M
Net Cash Per Share-$1.26
Tangible Book Value Per Share-$0.04
Margins
Gross margin is 65.55%, with operating margin of -59.70%, and net profit margin of -73.85%.
Gross Margin65.55%
Operating Margin-59.70%
Pretax Margin-73.71%
Net Profit Margin-73.85%
EBITDA Margin-60.58%
EBIT Margin-64.47%
Analyst Forecast
The average price target for NovaBay Pharma is $0.85, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$0.85
Price Target Upside49.12% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast-49.76%
EPS Growth Forecast99.13%